Link to paper Workel HH, van Rooij N, Plat A, Spierings DCJ, Fehrmann RSN, Nijman HW. de Bruyn M Abstract: Tumor-infiltrating CD8+ T cells (TIL) are of the utmost importance in anti-tumor immunity. CD103 defines tumor-resident memory T cells (TRM cells) associated with improved survival and response to immune checkpoint blockade (ICB) across human tumors. Co-expression…
Link to paper Knapen DJ, Kwee TC, Meijne EIM, Fehrmann RSN, de Vries EGE AbstractImmune checkpoint inhibitors (ICI) have improved outcomes for patients with advanced cancers, and results in increasing numbers of long-term survivors. For registration studies, progression-free survival and disease-free survival often serve as primary endpoints. This requires repeated computed tomography (CT) scans for…
Link to paper Boonstra PA, Wind TT, van Kruchten M, Schuuring E, Hospers GAP, van der Wekken AJ, de Groot DJ, Schröder CP, Fehrmann RSN, Reyners AKL AbstractResponse evaluation for cancer treatment consists primarily of clinical and radiological assessments. In addition, a limited number of serum biomarkers that assess treatment response are available for a…
On Monday February 24th, Kirsten Moek successfully defended his PhD thesis. See the summary description of his thesis below: Over the last decades many molecules and key pathways in cancer were identified, which facilitated a shift in anticancer drug development from DNA-damaging chemotherapy to a more personalized approach with targeted antibody therapeutics including antibody-drug conjugates (ADC)…
Link to paper Bhattacharya A, Bense RD, Urzúa-Traslaviña CG, de Vries EGE, van Vugt MATM, Fehrmann RSN AbstractCopy number alterations (CNAs) can promote tumor progression by altering gene expression levels. Due to transcriptional adaptive mechanisms, however, CNAs do not always translate proportionally into altered expression levels. By reanalyzing >34,000 gene expression profiles, we reveal the…
Link to paper van de Donk PP, Kist de Ruijter L, Lub-de Hooge MN, Brouwers AH, van der Wekken AJ, Oosting SF, Fehrmann RSN, de Groot DJA, de Vries EGE Immune checkpoint inhibitors (ICIs) have substantially changed the field of oncology over the past few years. ICIs offer an alternative treatment strategy by exploiting the…
Working environment “Using machine learning to unravel the ‘cancer-immune setpoint’ in cancers.” We have an exciting opportunity for a PhD student. The position will be for 4 years and should results in a PhD thesis at the University of Groningen. The PhD student position is available in the research group of dr. Rudolf Fehrmann. The…
Link to paper J.S. Hooiveld-Noeken, R.S.N. Fehrmann, E.G.E. de Vries, M. Jalving Highlights • Metastatic Merkel- and cutaneous squamous cell carcinoma are rare tumours. • Immunotherapy gives impressive responses but most patients do not survive long-term. • Small patients numbers prevent extensive biomarker research in clinical trials. • Pooled data from common and rare tumours…
On Wednesday November 20th, Rico Bense successfully defended his PhD thesis. See the summary description of his thesis below: In clinical practice, breast cancer is currently divided into subtypes based on immunohistochemical expression of the estrogen receptor and human epidermal growth factor receptor 2. These subtypes are crucial for treatment choice and outcome. However, even…
14th of November I gave an oral presentation at the 25th Oncologiedagen voor Nederland en Vlaanderen, Arnhem, the Netherlands. Below is the link to PDF with the slide presented. 2019-NVMO_OncologieDagen.pdf